CoChat

Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study

Open access
van de Borne, Philippe, Peeters, André, Janssens, Luc, Leone, Attilio, Lemmens, Robin, Verhaegen, Ann, De Meulemeester, Marc, Balthazar, Yohan, Heijmans, Stéphane, Calozet, Yvan, Paquot, Nicolas, Carlier, Stéphane, Hemelsoet, Dimitri, Bray, Sarah, Ray, Kausik K. · 2024 · Acta Cardiologica

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

Background Cardiovascular disease (CVD) is one of the leading causes of death in Belgium. Current strategies for the prevention and management of CVD focus on reducing low-density lipoprotein cholesterol (LDL-C) levels. This analysis assessed whether LDL-C goals, recommended by the European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines, were being achieved in a Belgian study population.Methods The cross-sectional, observational, DA VINCI study enrolled patients prescribed lipid-lowering therapy (LLT) between 21 June 2017 and 20 November 2018. Data for patients from Belgium were extracted for this country-specific analysis. Primary endpoint was the proportion of patients who achieved 2016 ESC/EAS risk-based LDL-C goals; attainment of 2019 risk-based LDL-C goals was evaluated post hoc.Results Of 497 enrolled patients, 41% were female and mean age was 68 years. Among subjects with an LDL-C measurement on stabilised LLT, moderate-intensity statin monotherapy was the most prescribed LLT regimen (59%). Overall, 63% of patients achieved their risk-based LDL-C goals according to the 2016 ESC/EAS guidelines. Among patients with established ASCVD, risk-based LDL-C goal attainment was higher in patients with peripheral arterial disease (53%) than patients with coronary (37%) and cerebrovascular disease (42%). According to the updated 2019 ESC/EAS guidelines, less than half (41%) of patients achieved their risk-based LDL-C goal. The proportion of primary and secondary prevention patients who achieved 2019 risk-based LDL-C goals was 59% and 18%, respectively.Conclusion These findings reveal a large gap between the LDL-C goals advocated by the ESC/EAS and the levels achieved in routine clinical practice in Belgium.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/00015385.2022.2030568

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Research works printed but not linked: 2

  1. Herink M Ito MK. Medication induced changes in lipid and lipoproteins [updated 2018 May 10]. In: Feingold KR Anawalt B Boyce A et al. editors. Endotext [Internet]. South Dartmouth (MA): MDText.com Inc.; 2000. Available from: https://www.ncbi.nlm.nih.gov/books/NBK326739/
  2. Goossens M, Kalyvas C, Kennel T, et al. De zorgtrajecten diabetes mellitus type 2 en chronische nierinsufficiëntie en kwaliteit van zorg. Brussel: Sciensano. Depotnummer; 2017–2019.

Cited by

See all 22

Metadata

Authors
van de Borne, P., Peeters, A., Janssens, L., Leone, A., Lemmens, R., Verhaegen, A., De Meulemeester, M., Balthazar, Y., Heijmans, S., Calozet, Y., Paquot, N., Carlier, S., Hemelsoet, D., Bray, S., & Ray, K. K.
Affiliations
  • Department of Cardiology, Erasme Hospital, University Libre of Brussels, Brussels, Belgium
  • Department of Neurology, Saint Luc University Clinic, Brussels, Belgium
  • Imelda Hospital (BE)
  • Centre Hospitalier Universitaire de Tivoli (BE)
  • KU Leuven (BE)
  • Antwerp University Hospital (BE)
  • GP, Private Practice, Gozée, Belgium
  • GP, Private Practice, Natoye, Belgium
  • GP, Private Practice, Linkebeek, Belgium
  • GP, Private Practice, Gribomont, Belgium
  • Centre Hospitalier Universitaire de Liège (BE)
  • Department of Cardiology, Ambroise Paré Hospital and University of Mons (UMONS), Mons, Belgium
  • Ghent University Hospital (BE)
  • Amgen (United Kingdom) (GB)
  • Imperial College London (GB)
Venue
Acta Cardiologica
Published
2022-04-20
Volume
79
Issue
1
Pages
20-29
ISSN
  • 0373-7934 (ISSN-L)
  • 0001-5385
OpenAlex
W4224240316
Cited by
22
References
26
Citations by year
2026: 5 · 2025: 5 · 2024: 5 · 2023: 6 · 2022: 1
FWCI
4.06
Type
journal article
Language
en
Open access
Locations
  • Acta cardiologica. Supplementum (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Lirias (KU Leuven) (submittedVersion, cc-by-nc-nd)
  • Open Repository and Bibliography (University of Liège) (submittedVersion, other-oa)
  • ORBi UMONS (submittedVersion, cc-by-nc-nd)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
  • Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
  • Spiral (Imperial College London) (submittedVersion, other-oa)
Funders
Amgen GmbH
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Keywords
lipid-lowering therapy, LDL cholesterol targets, ESC/EAS guidelines, statin monotherapy, guideline adherence, peripheral arterial disease, primary and secondary prevention, cardiovascular disease prevention, Belgium
MeSH terms
Aged, Belgium, Cardiovascular Diseases, Cross-Sectional Studies, Female, Goals, Humans, Cholesterol, LDL, Male, Risk Factors, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias, Atherosclerosis, Peripheral Arterial Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study. https://app.cochat.ai/papers/10.1080/00015385.2022.2030568
The paper
van de Borne, P., Peeters, A., Janssens, L., Leone, A., Lemmens, R., Verhaegen, A., De Meulemeester, M., Balthazar, Y., Heijmans, S., Calozet, Y., Paquot, N., Carlier, S., Hemelsoet, D., Bray, S., & Ray, K. K. (2024). Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study. Acta Cardiologica. https://doi.org/10.1080/00015385.2022.2030568

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.